Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Next Previous
Trial Profile

A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relmacabtagene-autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms RELIANCE
  • Sponsors Shanghai Ming Ju Biotechnology

Most Recent Events

  • 04 Jun 2024 Results (n=68) assessing Long-term survival outcomes in patients with relapsed/refractory large B-cell lymphoma after treatment of relma-cel presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 13 Dec 2022 Results (At data cut-off: 17 Dec 2021; n=28) assessing 6-month follow-up results of efficacy, safety, and pharmacokinetics, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 12 Dec 2022 Results presented in a JW Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top